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ABSTRACT
Introduction: Diseases caused by Streptococcus
pneumoniae represent a major public health
problem. The purpose of this study was to
compare, in the Japanese context, the
projected health benefits, costs and cost-
effectiveness of the latest generation of
pneumococcal conjugate vaccines which may
provide important insight into the potential
public health impact of interventions in the
context of local disease-specific epidemiology.
Methods: A Markov model was used to
compare two vaccination strategies which
involve routine infant immunization with
either the 13-valent pneumococcal conjugate
vaccine (PCV-13; Prevenar 13TM, Pfizer, Pearl
River, NY, USA) or the 10-valent pneumococcal
non-typeable Haemophilus influenzae protein D
conjugate vaccine (PHiD-CV; SynflorixTM,
GlaxoSmithKline Biologicals SA, Rixensart,
Belgium) over a time horizon of 5 years from
the healthcare provider and societal
perspectives. Estimates for key model
parameters were obtained from locally
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available databases and published literature.
Incremental benefits in terms of costs and
quality-adjusted life-year and cost-effectiveness
were assessed.
Results: A 3 ? 1 vaccination schedule for
infants with PHiD-CV is expected to have a
similar impact on invasive pneumococcal
disease and pneumonia and a larger impact on
acute otitis media-related outcomes compared
with PCV-13. Assuming price parity for these
vaccines, the model projected that vaccination
with PHiD-CV would result in cost savings of
1.9 and 3.9 billion Japanese yen from the
provider and societal perspectives, respectively.
This was largely due to a reduction in highly
prevalent acute otitis media. Vaccination with
PHiD-CV was expected to generate a gain of 433
quality-adjusted life-years compared to PCV-13
translating into dominance over PCV-13.
Sensitivity analyses showed robustness of
model outcome to changes in key model
parameters and substantiated that the model
outcome was consistently driven by the
incremental benefit of PHiD-CV in averting
acute otitis media.
Conclusion: In comparison to PCV-13,
vaccination with PHiD-CV is projected to be
cost saving for Japan from both the healthcare
provider and societal perspectives.
Keywords: Acute otitis media; Cost-
effectiveness; Invasive pneumococcal disease;
Japan; NTHi; PCV-13; PHiD-CV; Pneumonia;
Serotype
INTRODUCTION
Worldwide, pneumococcal disease is associated
with significant clinical and economic burden
on healthcare systems and the society.
Streptococcus pneumoniae (Sp) is responsible for
both invasive and non-invasive respiratory
infections causing diseases such as bacteremia,
meningitis, pneumonia and acute otitis media
(AOM) [1]. Vaccination with pneumococcal
conjugate vaccines (PCVs) remains the
cornerstone in preventing pneumococcal
disease. Over the last decade, pneumococcal
vaccines have been widely implemented in
childhood universal mass immunization
programs worldwide [1–7].
In Japan, the 7-valent PCV (PCV-7, Prevnar/
PrevenarTM, Pfizer, Pearl River, NY, USA) was
officially recommended for use in children aged
\5 years in 2010. PCV-7 was incorporated into
the routine national vaccination schedule for
children in April 2013 and eventually replaced
by the 13-valent PCV (PCV-13, Prevenar 13TM,
Pfizer, Pearl River, NY, USA) on November 1,
2013. Local surveillance studies have shown a
marked decrease in the prevalence of invasive
pneumococcal infections in children aged
\5 years {2011–2013 versus 2008–2010 as
reflected by a 51% reduction with an
associated incidence rate ratio (IRR) of 0.49
[95% confidence interval (CI) 0.37–0.63,
p\0.0001] [7]. In another study, it was
reported that the incidence of meningitis and
bacteremia attributable to vaccine serotypes
substantially dropped from 73.3 to 14.7% in
the period 2010–2013} [8]. Ihara et al. [9]
estimated that incidence rates per 100,000 in
children aged \5 years during 2012 (versus
2008–2010) for meningitis and bacteremia
changed from 2.8 to 0.8 (IRR 0.27; p\0.0001)
and 22.2 to 10.6 (IRR 0.48; p\0.0001),
respectively. Due to these dramatic declines in
disease burden due to PCV-7 types, non-PCV-7
serotype strains now constitute a predominant
cause of residual pneumococcal disease burden
in Japanese children [7–9]. A review of
epidemiology of pediatric infections in Japan
from 1990 onward shows that in addition to
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pneumococci, another respiratory pathogen,
non-typeable Haemophilus influenzae (NTHi),
causes significant morbidity in pediatric AOM,
and, to a lesser extent, plays a role in lower
respiratory diseases such as pneumonia [10, 11].
NTHi has been also reported as an infrequent
cause of invasive disease [12].
Bacterial infections often lead to high rates
of prescription and antibiotic use [1, 13]. This is
specifically the case with highly prevalent AOM
which is recognized as a leading indication for
the prescription of antibiotics to infants [13]. In
Japan, resistance to commonly used antibiotics
such as penicillins, macrolides and
cephalosporins is increasingly observed for
both Sp serotypes and NTHi, thereby rendering
treatment of such infections difficult [8, 12, 14,
15]. In the global context including Japan [8,
16], prevention of pneumococcal disease by
vaccination could play a significant role in
controlling the evolution of resistance which
is essential from a health policy point of view.
Both PCV-13 and the 10-valent
pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-
CV, SynflorixTM, GlaxoSmithKline Biologicals
SA, Rixensart, Belgium) have a broader
serotype coverage than PCV-7. PHiD-CV covers
three additional Sp serotypes (I, 5 and 7F)
compared with PCV-7. This vaccine was
designed to target Sp and potentially NTHi
infections due to the use of NTHi-derived
protein D as a carrier protein for the majority
of its conjugates [17, 18]. Compared to PHiD-
CV, PCV-13 contains three additional Sp
serotypes (3, 6A and 19A), but clinical
evidence shows that PHiD-CV offers protection
for the cross-reactive Sp serotypes 6A [17, 19]
and 19A [19–21]. To date, there is no conclusive
evidence that PCV-13 prevents invasive
pneumococcal disease (IPD), AOM or
pneumonia due to serotype 3 [22, 23].
The choice of PCV for national
immunization programs is usually determined
by a combination of multiple factors which
often include, but may not be limited to,
pathogen epidemiology prevalent in the target
group locally, vaccine formulation, vaccine
supply and cost-effectiveness considerations. It
is, therefore, important to assess the potential
benefits that the new generation vaccines, PCV-
13 or PHiD-CV, may offer in epidemiological
and economic terms to ensure efficient
allocation of healthcare resources based on
evidence-driven trade-offs of competing
healthcare options. The performed cost-
effectiveness evaluation presented in this
paper aims to estimate and compare the
potential impact of two childhood universal
immunization strategies: routine vaccination of
infants with PHiD-CV and PCV-13, the latter of
which is currently recommended for routine
immunization of infants in Japan.
MATERIALS AND METHODS
Model Overview
A previously published Markov model [24, 25]
was used to simulate the impact of
pneumococcal vaccination on the incidence of
Sp IPD, pneumonia and AOM, as well as NTHi-
AOM within a Japanese birth cohort
(n = 1,042,000 new-born) in terms of resource
use, cost implications and quality-adjusted life-
year (QALY) losses. Cost-effectiveness was
evaluated adopting the healthcare provider
and societal perspectives. The model was used
to compare 3 ? 1 regimens of PHiD-CV and
PCV-13 with vaccine doses administered at 2, 3,
4 and 13 months of life.
The basic model construct is visualized in
Fig. 1. Individuals were followed in the age-
Infect Dis Ther (2015) 4:93–112 95
stratified model over a time horizon of 5 years
with a cycle length of 1 month. During each
monthly cycle, the probability of an
individual entering a specific health state is
governed by age-specific Sp and NTHi-AOM
incidence rates and applicable vaccine efficacy
(VE) levels. These transition probabilities
determine hospitalization rates and frequency
of medical visits in conjunction with the
respective diseases considered in the model.
To the respective disease conditions, unit costs
and disease-specific disutilities were further
added. In each cycle of the model, cost
consequences and QALYs were estimated so
that costs and QALY losses accumulated until
the 5 year time horizon and converted into a
corresponding incremental cost-effectiveness
ratio (ICER) expressed in terms of costs per
QALY gained.
Demographics and Epidemiological Data
Annual number of births and age-specific
mortality rates were obtained from the
‘‘Estimation of population’’ (2013) [26] and the
‘‘Abridged life tables’’ (2012) [27], respectively,
available in the Official Statistics of Japan
(e-Stat) database. Epidemiological data used in
the model are provided in Table 1. Age-specific
incidence rates for IPD, hospitalized all-cause
pneumonia and AOM were taken from locally
available databases and published literature [9,
12, 14, 28]. The incidence rate for non-
hospitalized all-cause pneumonia was derived
by subtracting the number of pneumonia-
related hospital admissions from the total
number of pneumonia cases as provided by
the ‘‘Patient survey’’ [29]. The frequency of
meningitis sequelae was estimated from
Fig. 1 Model structure. AOM acute otitis media, B
bacteraemia,Mmeningitis, PCV-13 13-valent pneumococcal
conjugate vaccine, PHiD-CV 10-valent pneumococcal
non-typeable Haemophilus inﬂuenzae protein D conjugate
vaccine, P pneumonia
96 Infect Dis Ther (2015) 4:93–112
Kamiya et al. [28] and Iwata et al. [30]. The
frequency of myringotomy/tympanostomy
tube placement (TTP) procedures was obtained
from a retrospective survey (Table 1; for
additional details on the retrospective survey
see Appendix 1, Table 6).
Serotype distributions for IPD and AOM were
obtained from published reports addressing the
point in time when PCV-13 was introduced in
Japan [9, 12]. The proportion of AOM cases due
to Sp or NTHi was estimated by calculating the
ratio of confirmed number of Sp or NTHi-related
cases and the total number of pathogen-
confirmed cases (Table 1).
Direct Economic Burden, Resource Use
and Quality of Life
Retrospective database analyses were performed
involving two commercially available Japanese
claims databases. The EBM provider developed
by Medical Data Vision Co., Ltd (MDV-EBM
provider) and Japan Medical Data Centre
Claims Database (JMDC-CDB) were used to
Table 1 Model input for base case analysis: epidemiological data
Age-group 0 year 1 year 2 years 3 years 4 years Reference/assumption
Pneumococcal hospitalized meningitis
Incidence per 100,000 2.1 1.3 0.3 0.3 0.1 Ihara et al. [9]
Kamiya et al. [28]CFR 2.1%
Sequelae Neurological: 15.6% Iwata et al. [30]
Kamiya et al. [28]Hearing impairment: 3.2%
Pneumococcal hospitalized bacteremia
Incidence per 100,000 9.1 29.2 8.2 3.8 2.7 Ihara et al. [9]
Kamiya et al. [28]CFR 0.4%
All-cause hospitalized pneumonia
Incidence per 100,000 1748.3 Tanaka et al. [14]
CFR 0.091% Vital statistics (2012)
[54]
All-cause non-hospitalized pneumonia
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AOM acute otitis media, CFR case–fatality ratio, IPD invasive pneumococcal disease, NTHi non-typeable Haemophilus
inﬂuenzae, Sp Streptococcus pneumoniae, TTP tympanostomy tube placement
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gather information on resource use and costs
for IPD, pneumonia and AOM, respectively.
MDV-EBM provider is a hospital-based database
which covers approximately five million
patients and contains medical account data
(inpatient and outpatient) with detailed
inpatient information of patients of all ages.
JMDC-CDB is a health insurance claims
database which covers approximately 1% of
Japanese population aged \75 years and
contains data on inpatient, outpatient and
pharmacy expenditure for employees and their
family members in contracted health insurance
societies. The database analyses provided
estimates for the averages of the treatment
cost per acute episode for each disease, the
number of admission days and the number of
outpatient visits. The average treatment cost per
acute episode was calculated based on the
medical fee point for each procedure and
National Health Insurance drug prices at the
time of the medical treatment (Appendix 1,
Table 7).
Indirect costs (2013) were evaluated as lost
wages for parents providing care. The
productivity loss per acute disease episode was
equivalent to the number of work days lost
estimated by adding up the number of hospital
admission days and outpatient visits for the
child (1 visit = 0.5 day lost). Daily wages were
estimated on the basis of average annual salary
of individuals aged 18–49 years [3,330,415.73
Table 2 Model input for base case analysis: cost data
No. of acute episodes Average treatment cost per acute episode [JPY]
Average cost per acute episode
Meningitis (hospitalized) 57 767,447
Bacteremia (hospitalized) 137 340,905
All-cause pneumonia (hospitalized) 440 286,209
All-cause pneumonia (outpatient) 759 16,998
AOM with myringotomy 193 45,853
AOM without myringotomy 2,742 18,185
Average annual costs for long-term sequelae [JPY]
Neurological sequelae 452,260
Hearing loss 79,311
Work loss for parents No. of admission days No. of visits Average time lost from work (days)a
Meningitis—acute episode 13.8 1.5 14.6
Bacteremia (hospitalized) 7.2 1.4 7.9
All-cause pneumonia (hospitalized) 6.1 1.9 7.1
All-cause pneumonia (outpatient) NA 1.9 1.0
AOM with myringotomy/TTP 0.0 9.5 4.8
AOM without myringotomy 0.0 4.3 2.2
AOM acute otitis media, JPY Japanese yen, TTP tympanostomy tube placement, NA not applicable
a Estimated by adding up the number of hospital admission days and the number of outpatient visits (1 visit = 0.5 day lost)
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Japanese yen (JPY)] obtained from the ‘‘Basic
survey of wage structure’’ (2013) [31] and
‘‘Survey of Labour force’’ [32]. Time lost from
work for parents of sick children for each of the
disease outcomes is provided in Table 2.
Two types of utility values were used in the
model. Normative utility values were assumed
to be at the maximum due to the short time
horizon considered in the analysis. Disutility
values for the disease conditions were obtained
from sources provided in Table 3.
Vaccine Efficacy, Coverage and Costs
The time course of protection conferred by
vaccination was modeled in children of ages of
2 months until 5 years, with a ramp-up phase
coinciding with the course of vaccine dosing
from the age of 2 months until 13 months and a
full efficacy phase from the age of 13 months up
until 5 years. In the ramp-up phase the level of
protection established with the sequential doses
was assumed to be 50, 90, 90 and 100%
following the first three vaccine doses and
booster vaccination, respectively. VE estimates
used in this analysis were obtained from
published clinical trials and post-marketing
studies and validated by a panel of experts
(Table 4).
The impact of vaccination on IPD disease
burden was calculated by applying serotype-
specific VE to the respective Sp serotypes
causing disease in the target group for
vaccination. Serotype-specific VE data were
extrapolated from available efficacy and
effectiveness PCV trials. It is assumed that
PHiD-CV and PCV-13 have the same efficacy
for the ten common serotypes equal to the
average VE of the PCV-7 serotypes, as reported
by Whitney et al. [19]. Although serotypes 6A
and 19A are not contained in the PHiD-CV
vaccine, these serotypes belong functionally to
the same serogroups as serotypes 6B and 19F,
respectively, which are covered by the PHiD-CV
vaccine. Protection conferred by PHiD-CV
against cross-reactive serotypes 6A not
contained in PHiD-CV was set at 76% in the
light of similar antibody responses elicited by
PCV-7 and PHiD-CV [19]. For serotype 19A, VE
was set at 82.2% as observed for PHiD-CV in a
case–control study [19, 20]. To date, there is no
conclusive evidence that PCV-13 prevents
serotype 3 disease [33] and, therefore, VE was
assumed to be 0.0% in the base case analysis.
The model uses VE against World Health
Organization (WHO)-defined X-ray-confirmed
community-acquired pneumonia (CAP) (WHO-
CAP) as a surrogate measure of efficacy against
hospitalization for pneumonia. VE of PCVs,
including PHiD-CV against WHO-CAP and
suspected CAP, has been assessed in several
large-scale, randomized, controlled efficacy
trials, conducted in different settings [18, 34–
37]. In these trials, WHO-CAP and clinically
suspected CAP constituted the efficacy end
points. VE in terms of reduction in
hospitalization and outpatient consultation
was in the ranges of 20–35% and 6–7%,
respectively, based on defined end points not
discriminating between causative pathogens
[18, 34–37]. In the absence of PCV-13
estimates, and taking into account that
available pneumonia efficacy data cannot
easily predict the impact of a PCV on
pneumonia by relying on the number of
serotypes or support the notion that increasing
numbers of serotypes beyond PCV-7 will result
in a detectable increase in protection against
pneumonia [38], the Clinical Otitis Media &
Pneumonia Study (COMPAS, ClinicalTrials.gov
Identifier: NCT00466947) efficacy estimates
against WHO-CAP (23.4%) and suspected CAP
(7.3%) for PHiD-CV were applied to PCV-13 as
well [18].
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VE against AOM without myringotomy/TTP
procedures was ascertained based on Sp and
NTHi prevalence. VE against Sp vaccine
serotypes was assumed to be 69.9% for PHiD-
CV [18]. Similar to VE estimation for IPD,
partial protection efficacy levels of 63.7%
against 6A [17] and 60.7% against serotype
19A were assumed for PHiD-CV. In the base
case analysis, the same VE was assumed for the
PHiD-CV serotypes in PCV-13 for which AOM-
related efficacy estimates were not available.
The same assumption was also used for the
additional PCV-13 serotypes except for
serotype 3 (Table 4). VE against serotype 3
was assumed to be 0.0% for both vaccines, as
PHiD-CV does not include serotype 3 and
PCV-13 effectiveness against serotype 3 is not
confirmed. Although PCV-7 VE against Sp non-
vaccine types and NTHi has been reported as
-33% and -11%, respectively (FIN-OM study
[39], ClinicalTrials.gov Identifier:
NCT00378417), we made conservative
assumptions of 0.0%. VE against Sp non-
vaccine type AOM was assumed to be 0.0%
for both vaccines (based on COMPAS for
PHiD-CV [18]). VE against NTHi-AOM was
assumed to be 21.5% and 0.0% for PHiD-CV
and PCV-13, respectively [17, 18, 39].
Reduction in myringotomy/TTP was
estimated on the basis of PCV-7 efficacy
obtained from a Kaiser Permanente study [40]
and the FinOM study [41]. These reports
indicate low VE against TTP at high
incidences of TTP. This relationship was
modeled by extrapolating PCV-13 and PHiD-
CV VE from that of PCV-7. Extrapolated VE
estimates were well in agreement with the
findings of the FinIP study [42]. The likely
higher efficacy of PHiD-CV compared to PCV-
13 for AOM is reflected in the estimates of VE
against myringotomy/TTP (Table 4).
For simplicity, vaccination coverage was
assumed as 100% in the base case. Price parity
of 7,776 JPY was assumed for both PHiD-CV and
PCV-13. The administration cost per vaccine
dose was assumed to be 4,212 JPY [43].




Disutility per episode (short-term)
Meningitis (hospitalized) 0.023 Bennett et al. [55]
Bacteremia (hospitalized) 0.008
Pneumonia (hospitalized) 0.008 Assumed to be the same as for hospitalized bacteremia
Pneumonia (outpatient) 0.006 Bennett et al. [55]
AOM without myringotomy 0.005 Oh et al. [56]
AOM with myringotomy/TTP
procedures
0.005 Assumed to be the same as for AOM without myringotomy
Disutility per year (long term)
Neurological sequelae from meningitis 0.400 Morrow et al. [57]
Hearing loss from meningitis 0.200 Morrow et al. [57], Cheng et al. [58]
AOM acute otitis media, TTP tympanostomy tube placement
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Table 4 Model input for base case analysis: vaccine efﬁcacy
VE% (95% CI) Reference/assumption
PHiD-CV PCV-13
IPD
10 common serotypes for PHiD-CV and PCV-13 94.7% (87–100) 94.7% (87–100) Whitney et al. [19]
Serotype 3 0.0% (0–0) 0.0% (0–89) Expert opinion
Moore et al. [33]
Serotype 6A 76.0% (39–90) 94.7% (87–100) Whitney et al. [19]
Serotype 19A 82.2% (11–96) 94.7% (87–100) Domingues et al. [20]
Whitney et al. [19]
Pneumonia
Hospitalization 23.4% (9–36) 23.4% (9–36) Tregnaghi et al. [18]
Non-hospitalization 7.3% (2–12) 7.3% (2–12) Tregnaghi et al. [18]
AOM without myringotomy
10 common serotypes for PHiD-CV and PCV-13 69.9% (30–87) 69.9% (30–87) Tregnaghi et al. [18]
Serotype 3 0.0% (0–0) 0.0% (0–0) Expert opinion
Serotype 6A 63.7% (-14–88) 69.9% (30–87) Prymula et al. [17]
Tregnaghi et al. [18]
Serotype 19A 60.7% (8–71) 69.9% (30–87) Expert opinion
Tregnaghi et al. [18]
Others 0.0% (-33–15) 0.0% (-33–1) Tregnaghi et al. [18]
Prymula et al. [17]
Eskola et al. [39]
Expert opinion
NTHi 21.5% (0–35) 0.0% (-11–8) Tregnaghi et al. [18]
Prymula et al. [17]
Eskola et al. [39]
Expert opinion
AOM with myringotomy/TTP
Myringotomy/TTP 40.4% (-9–75) 27.0% (-14–50) Fireman et al. [40]
Palmu et al. [41]
The 95% CI values were used as the boundary in the sensitivity analyses
AOM acute otitis media, PCV-13 13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal NTHi
protein D conjugate vaccine, TTP tympanostomy tube placement
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Analyses
Under base case assumptions, numbers of
deaths and cases of IPD, all-cause pneumonia
(hospitalized and non-hospitalized), and AOM
(with and without myringotomy/TTP
procedures) were estimated for both vaccines.
The direct costs, including vaccination and
treatment, and the indirect costs for each
disease outcome were estimated. All costs are
reported in JPY. The effects between the two
vaccination strategies are reported as QALYs
and life-years (LYs) gained, which are related to
the defined health outcome that was
determined. The ICER was estimated. A 3.0%
discount rate was used for both cost and
outcomes to allow a proper assessment of the
benefit from the start of vaccination.
In addition to the base case analysis, several
scenarios were modeled based on local interest
wherein hypothetical considerations and
different combinations of parameters were
used to populate the model to examine their
potential impact on cost and effect outcomes
(Appendix 1). To account for uncertainty in the
key model assumptions, two types of sensitivity
analyses were performed. A one-way sensitivity
analysis was done in which model parameters
such as VE, disease epidemiology and
management were varied within a pre-
specified range of ±20% if 95% CI was
unavailable. A probabilistic sensitivity analysis
(PSA) was performed by sampling
simultaneously, from probability distributions
linked to VE (log-normal distribution), disease
incidence (beta distribution), disutility values
(beta distribution) and costs (triangular
distribution). An ICER below 5,000,000 (5
million) JPY per QALY gained was considered
cost-effective for Japan [44]. All the analyses
were done using Microsoft ExcelTM 2007/2010
(Microsoft Corporation, Washington, USA).
Trademark Disclosure
Synflorix is a trademark of the GSK group of
companies, Prevnar/Prevenar is a trademark of
Wyeth/Pfizer and Prevnar 13 is a trademark of
Pfizer.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. Where applicable, data were
obtained from previously conducted studies.
RESULTS
Base Case: Impact of Vaccination
on Disease Burden and Cost-Effectiveness
In a birth cohort of 1,042,000 newborn in Japan
(2013), model projections indicate that PCV-13
and PHiD-CV were expected to provide
equivalent impact in the prevention of deaths
caused by IPD and all-cause pneumonia. While
the estimated impact of PHiD-CV and PCV-13
were broadly similar for pneumococcal
meningitis and bacteremia, and all-cause
pneumonia, the model showed that PHiD-CV
was expected to prevent a significantly larger
number of AOM cases (92,467 AOM episodes)
compared to PCV-13 (Table 5).
By assuming price parity for both PHiD-CV
and PCV-13, a vaccination program with PCV-
13 is shown to generate marginal cost savings
for both meningitis and bacteremia; while
PHiD-CV vaccination was expected to save an
additional 1.9 billion JPY and 2.0 billion JPY in
direct costs and indirect costs (undiscounted),
respectively. The aggregate cost savings of 1.9
(direct costs, discounted) and 3.9 billion JPY
(direct and indirect costs, discounted) with
PHiD-CV were due to a reduction in AOM-
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related cases and myringotomy/TTP procedures
resulting in a QALY gain of 433 (462
undiscounted) compared to PCV-13. Cost
consequences and QALYs gain translated into
ICERs of -4.4 million JPY and -9.1 million JPY
per QALY gained for the provider and societal
perspectives, thereby showing dominance of
PHiD-CV over PCV-13 in the base case analysis
(Table 5).
Scenario and Sensitivity Analysis
For most of the modeled scenarios, PHiD-CV
vaccination, in comparison to PCV-13, is
Table 5 Model outcomes for base case analysis
PHiD-CV PCV-13 Difference (PHiD-CV-PCV-13)
Disease-related outcomes
Deaths due to IPDs, all-cause pneumonia and AOM 66 66 0
Cases of pneumococcal meningitis 24 23 1
Cases of pneumococcal bacteremia 286 268 18
Cases of all-cause pneumonia 479,841 479,841 0
Cases of AOM 1,228,971 1,321,438 -92,467
Cases of meningitis sequelae 4 4 0
Economic outcomes [JPY]
Direct costs (undiscounted)
Vaccination 49,916,940,488 49,916,940,845 -357
Pneumococcal meningitis 18,258,447 17,305,345 953,102
Meningitis sequelae 7,341,933 6,988,325 353,608
Pneumococcal bacteremia 97,762,048 91,511,944 6,250,104
All-cause pneumonia 27,229,316,268 27,229,317,920 -1,652
AOM 24,033,839,820 26,066,680,756 -2,032,840,936
Indirect costs
Wages lost (acute episode) 34,436,663,525 36,591,103,326 -2,154,439,801
Cost-effectiveness outcomes (undiscounted)
Total direct costs (JPY) 101,303,459,004 103,328,745,135 -2,025,286,132
Total direct and indirect costs (JPY) 135,740,122,528 139,919,848,461 -4,179,725,932
Total LYs gained 5,197,521 5,197,522 0
Total QALYs gained 5,188,347 5,187,885 462
ICER (healthcare provider perspective) – – Dominanta
ICER (societal perspective) – – Dominanta
Cost-effectiveness outcomes (discounted)
Total direct costs (JPY) 97,339,123,665 99,237,387,104 -1,898,263,439
Total direct and indirect costs (JPY) 129,652,473,264 133,570,122,617 -3,917,649,353
Total LYs gained 4,837,775 4,837,775 0
Total QALYs gained 4,829,175 4,828,742 433
ICER (healthcare provider perspective) – – Dominanta
ICER (societal perspective) – – Dominanta
AOM acute otitis media, JPY Japanese yen, ICER incremental cost-effectiveness ratio, IPD invasive pneumococcal disease, LY life-year, PCV-13 13-valent
pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal non-typeable Haemophilus inﬂuenzae protein D conjugate vaccine, QALY quality-
adjusted life-years
a PHiD-CV is dominant because it exhibits both lower costs and higher number of QALYs (effectiveness) compared to PCV-13
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expected to generate larger QALYs gains and
lower costs from both the healthcare provider
and societal perspectives, which translated into
dominance of vaccination with PHiD-CV over
PCV-13 (Fig. 2). One-way sensitivity analyses
substantiated AOM/TTP-related parameters as
consistent influential drivers of model outcome.
Sensitivity analyses also demonstrated the
robustness of the base case model outcome to
changes in key model parameters and
assumptions. Specifically, the one-way
sensitivity analyses showed that the ICERs
were most sensitive to PHiD-CV efficacy
against NTHi-AOM, percentage reduction in
myringotomy/TTP procedures and changes in
other AOM-related parameters from both the
provider and societal perspectives. Despite
varying these parameters, PHiD-CV
vaccination was either cost saving or cost-
effective compared to PCV-13 vaccination
(Fig. 3).
In the PSA, vaccination PHiD-CV is shown to
dominate PCV-13 in terms of QALYs gained and
cost savings (89% and 90% of the simulations in
provider and societal perspectives, respectively).
In contrast, only 4% of the simulations
indicated that vaccination with PCV-13 was
expected to dominate PHiD-CV in both
perspectives. The probability that PHiD-CV
vaccination was cost-effective compared to
Fig. 2 Scenario analyses. a Healthcare provider perspec-
tive, b societal perspective. 1 No protection for PHiD-CV
against cross-reactive types 6A and 19A; 2 no efﬁcacy of
PHiD-CV against NTHi-AOM; 3 decreased VE for
reduction of myringotomy; 4 no efﬁcacy of PHiD-CV
against NTHi-AOM and decreased VE for reduction of
myringotomy; 5 decreased efﬁcacy of PCV-13 against Sp-
AOM; 6 decreased VE for reduction of myringotomy; 7
decreased efﬁcacy of PCV-13 against Sp-AOM and
decreased VE for reduction of myringotomy. AOM acute
otitis media, JPY Japanese yen, PCV-13 13-valent pneu-
mococcal conjugate vaccine, PHiD-CV 10-valent pneu-
mococcal non-typeable Haemophilus inﬂuenzae protein D
conjugate vaccine, QALY quality-adjusted life-years, Sp
Streptococcus pneumonia
b
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PCV-13 vaccination was estimated to be 93%
from both perspectives (Fig. 4).
DISCUSSION
A recent study indicates that both, the disease
burden and costs associated with highly
prevalent AOM outweigh IPD due to the high
volume of outpatient consultations,
myringotomy/TTP procedures and utilization
of antibiotics [45]. A vaccine that confers
significant protection against AOM and the
associated frequent use of antibiotics could be
advantageous in settings with highly prevalent
AOM disease. PHiD-CV may help in the control
of NTHi-related AOM in addition to Sp-related
AOM [17, 18, 40, 45–49].
The potential impact of PHiD-CV and PCV-
13 on IPD and AOM incidence was compared in
children aged \5 years using a previously
published age-stratified Markov model [24, 25]
that was populated with epidemiological,
resource use and cost data specific for Japan.
The model findings demonstrate a similar
impact on overall IPD outcomes with either
vaccine. In terms of IPD incidence and
associated deaths, a similar impact was
predicted for either of the formulations, in
line with likely marginal, if any at all,
differences in protection reflected by serotype-
specific VE for vaccine and vaccine-related
serotypes 6A [19] and 19A [19–21]. Similarly,
identical VE against pneumonia was assumed
which resulted in equivalent impact on
pneumonia-related outcomes. However, PHiD-
CV is projected to have a larger public health
and economic impact owing to the high disease
incidence of AOM in Japan [12] and its likely
larger effects against this clinical syndrome
compared to PCV-13. Although, a large body
of evidence, including both preclinical and
clinical research, points to the potential NTHi-
related impact of PHiD-CV in AOM [17, 18, 46,
48, 50], rather conservative assumptions have
been made in this cost-effectiveness model with
respect to the magnitude of its NTHi-effect in
AOM. Nonetheless, an incremental benefit with
PHiD-CV over PCV-13 is observed for NTHi-
related AOM outcomes.
Given the current epidemiological landscape
in Japan and our model findings regarding
impact on disease outcomes, it is likely that
childhood immunization with PHiD-CV in
Japan will result in better cost-offsets and
health gain compared to PCV-13. Under base
case assumptions, PHiD-CV vaccination of
infants is a cost-saving modality compared
with PCV-13 vaccination from both the
healthcare provider and societal perspectives.
Sensitivity analyses showed that ICER was
robust to changes in key model parameters and
confirmed a consistent impact of AOM
prevention on model outcome. The model
outcome was driven by the incremental benefit
of PHiD-CV in terms of preventing highly
prevalent AOM disease and myringotomy/TTP
procedures. In the light of the publications of
[45] which has shown that PHiD-CV vaccination
reduced the rates of antibiotic prescriptions in
outpatient settings, one may therefore expect
that the introduction of PHiD-CV in Japan will
reduce the frequency of antibiotic use in
conjunction with highly prevalent AOM and
consequently likely contribute to the control of
increasing antibiotic resistance of NTHi bacteria
in addition to Sp [10, 12].
While the cost-effectiveness profiles of
different pneumococcal vaccination strategies
in several countries have been previously
described using similar tools such as Markov
cohort models [24, 25], a direct comparison of
results and, therefore, generalizability are
limited due to the differences in the local
epidemiology of the disease under
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investigation and healthcare systems specific to
each country. Apart from generalizability, there
are several study limitations that need to be
addressed. Reliable epidemiological data such as
incidence in individuals aged [5 years are not
available for Japan; hence, a time horizon of
5 years was used in the base case analysis. While
waning of VE is usually assumed from 2 years
after vaccination, however, due to the short
time horizon this factor was not considered in
the analysis. In addition, while productivity
losses due to the treatment of acute disease
were evaluated, productivity losses due to long-
term sequelae were not estimated due to lack of
data. The incidence of pneumonia was based on
information for the time period prior to PCV-7
implementation due to limited data from post-
PCV-7 vaccination implementation in Japan,
implying that there is a need for up-to-date
epidemiological data for future epidemiological
and cost-effectiveness studies. In our analysis,
herd protection was not assumed given that the
analytical time horizon was restricted to child
age cohorts. To our knowledge, the implications
of herd protection have not been addressed in
any of the cost-effectiveness analyses published
for Japan [51, 52]. Previous studies have
examined the potential magnitude of such
indirect effects including herd protection and
serotype replacement [38]. The findings varied
considerably, therefore providing the rationale
for not including herd protection in the current
model [53]. To assess the true cost-effectiveness
profiles of PCV vaccination modalities and
explore sustainability of the selected PCV in
Japan, it is suggested to investigate the
importance of these factors in the overall
impact of vaccination.
CONCLUSIONS
This cost-effectiveness analysis shows that a
3 ? 1 universal childhood vaccination program
using PHiD-CV, priced at parity with PCV-13, is
expected to be cost saving compared to an
identical vaccination program involving PCV-
13, specifically in providing incremental
Fig. 4 Probabilistic sensitivity analysis. a Healthcare pro-
vider perspective, b societal perspective. JPY Japanese yen,
QALY quality-adjusted life-years, ﬁlled square point esti-
mate of base case analysis, the inclination of the line
passing a point (0, 0) represents the cost-effectiveness
threshold for Japan (5 million JPY per QALY gained)
Fig. 3 One-way sensitivity analyses. a Healthcare provider
perspective, b societal perspective. AOM acute otitis media,
JPY Japanese yen, NTHi non-typeable Haemophilus
inﬂuenza, nVT non-vaccine type, PCV-13 13-valent
pneumococcal conjugate vaccine, PHiD-CV 10-valent
pneumococcal non-typeable Haemophilus inﬂuenzae pro-
tein D conjugate vaccine, QALY quality-adjusted life-years,
Sp Streptococcus pneumoniae, VT vaccine type
b
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benefits with AOM, translating into fewer cases
of AOM and myringotomy/TTP procedures, as
well as associated costs, both from healthcare
provider and societal perspectives. Given the
importance of pneumococcal serotype coverage
and associated serotype-specific VE levels
including protection against cross-reactive
serotypes, modeling exercises accommodating
these aspects adequately provide valuable
insights into how these factors may play out
in the context of local epidemiology.
Nonetheless, it is important to continuously
and actively monitor epidemiological changes
effected by pneumococcal vaccination to
inform future decision making and healthcare
policy in Japan.
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AOM acute otitis media, ICD-10 the international statistical classiﬁcation of diseases and related health problems 10th
revision
a One episode was deﬁned as a series of treatment with a visit interval of less than 1 month from the initial diagnosis. When
the treatment was restarted after the visit interval of 1 month or more, it was regarded as a different episode
b Codes have been used to extract cost information
Table 7 Scenario analyses
PHiD-CV PCV-13
Scenario
(1) Efﬁcacy of IPDs 6A and 19A: 0.0% Base case
(2) Efﬁcacy of NTHi-AOM 0.0% Base case
(3) % reduction in myringotomy 26.1%a Base case
(4) = (2) ? (3) NTHi-AOM efﬁcacy: 0.0% Base case
% reduction in myringotomy: 26.1%
(5) Efﬁcacy of Sp-AOM Base case Common vaccine serotypes, 6A,
and 19A: 57.0% (Eskola et al.) [39]
(6) % reduction in myringotomy Base case 22.0%b
(7) = (5) ? (6) Base case Common vaccine serotypes, 6A and 19A: 57.0%
% reduction in myringotomy/TTP: 22.0%
AOM acute otitis media, IPD invasive pneumococcal disease, PCV-13 13-valent pneumococcal conjugate vaccine, PHiD-CV
10-valent pneumococcal non-typeable Haemophilus inﬂuenzae protein D conjugate vaccine, Sp Streptococcus pneumoniae
a Calculated value in case of no efﬁcacy of PHiD-CV against NTHi-AOM
b Calculated value in case of the efﬁcacy of PCV-13 against Sp vaccine serotype AOM taken from FIN-OM study [39]
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